Nexgel, Inc.
NXGL Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$4.26
KIRA · Stoqly’s AI analyst, in plain words
- Nexgel, Inc. had $11.4M of revenue in fiscal 2025, up 31.5% on the year before. Over five years, revenue changed +76.1% a year on average.
- Its operating margin was −29.3%, up 11.6 pts: of every 100 in sales, about −29 is left after running the business.
- Nexgel, Inc. lost $3.0M in fiscal 2025.
- Free cash flow was −$1.4M in fiscal 2025, −12.1% of revenue.
- Nexgel, Inc. owes $0.6M more than it holds in cash.
Market cap
$38.4M
P/E
—
Revenue
$11.4M
Net income
−$3.0M
Free cash flow
−$1.4M
Operating margin
−29.3%
Nexgel, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+31.5%
Yes. Sales grew 31.5% last year.
Does it make a profit?
−26.3%
No. It lost money last year.
Does profit turn into cash?
−12.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nexgel, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- NEXGEL, INC.
- CIK
- 0001468929
Nexgel, Inc. · NXGL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.6M | $2.0M | $4.1M | $8.7M | $11.4M |
| Revenue growth | 130.1% | 32.0% | 99.7% | 112.5% | 31.5% |
| Gross margin | 0.5% | 12.5% | 9.1% | 31.6% | 39.5% |
| Operating margin | −165.7% | −163.5% | −85.0% | −40.9% | −29.3% |
| Net income | −$4.3M | −$4.7M | −$3.2M | −$3.3M | −$3.0M |
| Net margin | −277.9% | −231.7% | −77.2% | −37.8% | −26.3% |
| Diluted EPS | −$1.45 | −$0.85 | −$0.56 | −$0.50 | −$0.38 |
| Cash | |||||
| Cash from operations | −$2.8M | −$3.0M | −$3.2M | −$3.9M | −$1.3M |
| Capital expenditure | $0.3M | $0.1M | $0.7M | $0.4M | $0.1M |
| Free cash flow | −$3.0M | −$3.1M | −$3.9M | −$4.3M | −$1.4M |
| FCF margin | −194.8% | −150.8% | −96.2% | −49.6% | −12.1% |
| Share count change | 32.2% | 87.1% | 1.7% | 14.8% | 20.6% |
| Debt and strength | |||||
| Cash and short-term investments | $13.4M | $6.6M | $2.7M | $1.8M | $0.3M |
| Debt incl. finance leases | — | $0.3M | $0.8M | $1.1M | $0.9M |
| Shareholders' equity | $12.1M | $7.6M | $4.7M | $5.8M | $4.5M |
| Current ratio | 4.8x | 8.7x | 2.0x | 2.1x | 1.5x |
| Interest coverage | — | −2.5x | −231.8x | −43.9x | −98.6x |
| Returns and quality | |||||
| Return on capital | — | −201.7% | −96.9% | −60.6% | −56.0% |
| Return on equity | −70.9% | −48.1% | −51.2% | −62.8% | −58.7% |
| Return on tangible equity | −36.7% | −65.0% | −97.3% | −85.9% | −113.2% |
| Piotroski F-score | 4 | 4 | 2 | 5 | 5 |
| Altman Z'' | 4.5 | 1.3 | −4.5 | −4.7 | −7.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
22%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nexgel, Inc. · NXGL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.26 a share, the company is worth $38.4M.
Source: SEC EDGAR XBRL filings (CIK 0001468929). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.